cGAS-STING pathway targeted therapies and their applications in the treatment of high-grade glioma.

Journal Article (Journal Article;Review)

Median survival of patients with glioblastoma (GBM) treated with standard of care which consists of maximal safe resection of the contrast-enhancing portion of the tumor followed by radiation therapy with concomitant adjuvant temozolomide (TMZ) remains 15 months. The tumor microenvironment (TME) is known to contain immune suppressive myeloid cells with minimal effector T cell infiltration. Stimulator of interferon genes (STING) is an important activator of immune response and results in production of Type 1 interferon and antigen presentation by myeloid cells. This review will discuss important developments in STING agonists, potential biomarkers for STING response, and new combinatorial therapeutic approaches in gliomas.

Full Text

Duke Authors

Cited Authors

  • Tripathi, S; Najem, H; Mahajan, AS; Zhang, P; Low, JT; Stegh, AH; Curran, MA; Ashley, DM; James, CD; Heimberger, AB

Published Date

  • 2022

Published In

Volume / Issue

  • 11 /

Start / End Page

  • 1010 -

PubMed ID

  • 36324813

Pubmed Central ID

  • PMC9597127

Electronic International Standard Serial Number (EISSN)

  • 2046-1402

Digital Object Identifier (DOI)

  • 10.12688/f1000research.125163.1


  • eng

Conference Location

  • England